Chinese Cell Therapy Firm Yuanmai Cellular Biosciences Secures New Funding and Advances In Vivo Gene Editing Pipeline

Recently,The Investment Decision Committee of the Nanjing University Science and Technology Achievement Transformation Angel Fund and the Nanjing Future Industry Angel Fund has approved the investment project of Nanjing Yuanmai Cell Biotechnology Co., Ltd.(hereinafter referred to as the Company or Yuanmai Cell), which will complete the signing of the investment agreement in the near future. This investment marks the official launch of the Nanjing University Science and Technology Achievement Transformation Angel Fund, with the Nanjing Future Industry Angel Fund gaining further momentum.

Yuanmai Cell is registered in Jiangbei New Area, Nanjing City, and was jointly established by the research team of Shen Pingping from Nanjing University and senior pharmaceutical executives.

Yuanmai Cell focuses on developing treatment technologies for fibrotic diseases and solid tumors, committed to addressing unmet clinical needs. It has currently established four core technology platforms with independent intellectual property rights: a high-throughput screening system for anti-fibrotic payloads, a CAR functional module library, an in vitro gene editing system, and an in vivo gene editing delivery system. Through its in vivo gene editing delivery technology, Yuanmai Cell advances the engineering transformation of macrophages from in vitro transfection to in vivo editing, achieving a generational leap from cell therapy to biopharmaceuticals. Its project targeting liver fibrosis is already undergoing investigator-initiated clinical trials.（IIT）。

Professor Shen Pingping, the scientific founder of the company, was selected for the Ministry of Education's "New Century Excellent Talents Support Program." She is currently a professor at the School of Life Sciences, Nanjing University, and serves as the Principal Investigator (PI) at the State Key Laboratory of Pharmaceutical Biotechnology — Gulou Hospital Research Center.(Chief Researcher)Under the leadership of Professor Shen, his research team has achieved remarkable results in recent years, receiving funding from a variety of sources such as the National Key R&D Program, the NSFC Innovative Research Group, the NSFC Major Research Plan, the Ministry of Education's New Century Excellent Talents Support Program, and Jiangsu Province's Major Frontier Technology Projects. Professor Shen has also been recognized as the first contributor, winning numerous awards including the 2014 Jiangsu Province Science and Technology First Prize and the "Outstanding Achievement Award" at the 12th World Congress on Advances in Oncology. Professor Shen’s team has long been committed to the research of "Macrophage Immune Regulation and Related Immunotherapy Technologies," achieving a series of original results.

Yuanmai Cell is a typical example of the transformation of university scientific research achievements. The investment decision in Yuanmai Cell fully demonstrates the crucial role of government-guided funds in fostering new productive forces, significantly accelerating the transformation of university scientific and technological achievements into practical productivity. It promotes the precise alignment of cutting-edge university technologies with market demands, further enhancing Nanjing's concentration and influence in the gene and cell therapy industry chain, and laying a solid foundation for the high-quality development of Nanjing's biopharmaceuticals industry.